Related Experiment Video
Updated: Feb 24, 2026

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
Published on: March 4, 2021
Part 2: Pre-Clinical Assessment of Medical Displays for Regulatory Evaluation
Aldo Badano1, Wei-Chung Cheng1, Brendan J O'Leary1
1Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Bldg 62, Room 3116, Silver Spring, MD 20993; telephone 301/796-2534.
Abstract:
Challenges are emerging with regard to the pre-clinical, regulatory assessment of display systems used for viewing and interpreting medical images. This article discusses those, and also the types of evidence that might be relevant to the evaluation of mobile image-viewing devices, true-color devices with applications in digital microscopy, and 3-D medical displays as discussed in Part 1.
More Related Videos
08:38Electroretinogram Recording for Infants and Children under Anesthesia to Achieve Optimal Dark Adaptation and International Standards
Published on: September 3, 2020
12:04Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
Published on: May 9, 2018
Related Concept Videos
Preclinical Development: Overview
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Clinical Trials: Overview